explore -WSS

explore

author：Wikipedia 2025-09-28 01:37:52 - browse：8424

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Violet CEO on training clinicians to promote more inclusive care

hotspot

WSS

Physician subsidies by hospitals soar in wake of No Surprises Act

Telehealth options flood the market as retailers push virtual care

Readout Newsletter: XBI biotech index, Akero Therapeutics

Meta's Zuckerberg and Chan on track to put $50 billion into science

Readout Newsletter: What happened with Sarepta's Duchenne data

Readout Newsletter: What happened with Sarepta's Duchenne data

entertainment

explore

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: What happened with Sarepta's Duchenne data

Peter Hotez and the public health issue of online harassment

Readout Newsletter: XBI biotech index, Akero Therapeutics

The cancer drug shortage isn’t new — and neither are the solutions

Readout Newsletter: What happened with Sarepta's Duchenne data

The high cost of giving birth even with insurance

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

hotspot

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Paying for Covid pills will soon shift to insurers

CDC recommends rationing of RSV shot due to shortages

Readout Newsletter: XBI biotech index, Akero Therapeutics

Grail spinoff by Illumina should end disastrous merger attempt

Readout Newsletter: New research from Sanofi, Regeneron, etc.

hotspot

leisure time

focus

hotspot